Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes

Parkinsonism and Related Disorders

Volumn 15, Issue 4, 2009, Pages 300-306

  Hasegawa, Kazuko ^a   Stoessl, A Jon ^b   Yokoyama, Teruo ^c   Kowa, Hisayuki ^a   Wszolek, Zbigniew K ^d   Yagishita, Saburo ^a  

^a SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Hakone National Hospital   (Japan)

^d MAYO CLINIC   (United States)

Author keywords

Nigral degeneration; PARK8; PET

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMANTADINE; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; TRIHEXYPHENIDYL;

ARTICLE; AUTOPSY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG UPTAKE; FAMILIAL DISEASE; FEMALE; GENE MUTATION; HEART SCINTISCANNING; HUMAN; LEWY BODY; LOW BACK PAIN; MALE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; ONSET AGE; PARKINSON DISEASE; PEDIGREE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISOLEUCINE; JAPAN; MALE; MIDDLE AGED; MUTATION; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN-SERINE-THREONINE KINASES; RADIOPHARMACEUTICALS; TETRABENAZINE; TYROSINE;

EID: 64249149785     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.07.010     Document Type: Article

References (23)

1. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., and Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51 (2002) 296-301
2. Hasegawa K., Funayama M., Matsuura N., Furusawa H., Sakai F., Kowa H., et al. Analysis of alpha-synuclein, parkin, tau, and UCH-L1 in a Japanese family with autosomal dominant parkinsonism. Eur Neurol 46 (2001) 20-24
3. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
4. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
5. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., et al. International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7 (2008) 583-590
6. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57 (2005) 918-921
7. Nukada H., Kowa H., Saitoh T., Tazaki Y., and Miura S. A big family of paralysis agitans. Rinsho Shinkeigaku 18 (1978) 627-634 [Translated by the authors] [Japanese]
8. Adams J.R., van Netten H., Schulzer M., Mak E., Mckenzie J., Strongosky A., et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128 (2005) 2777-2785
9. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67 (1999) 189-194
10. Lowe J.S., and Leigh N. Disorders of movement and system degenerations. In: Graham D.I., and Lantos P.L. (Eds). Greenfield's neuropathology. 7th ed. vol. 2 (2002), Arnold, New York 325-372
11. Inoue M., Yagishita S., Ryo M., Hasegawa K., Amano N., and Matsushita M. The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems. Acta Neuropathol (Berl) 93 (1997) 585-591
12. Ishizawa T., Mattila P., Davies P., Wang D., and Dickson D.W. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62 (2003) 389-397
13. Saito Y., Ruberu N.N., Sawabe M., Arai T., Kazama H., Hosoi T., et al. Lewy body-related α-synucleinopathy in aging. J Neuropathol Exp Neurol 63 (2004) 742-749
14. Goldstein D.S., Imrich R., Peckham E., Holmes C., Lopez G., Crews C., et al. Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology 69 (2007) 1580-1584
15. Wszolek Z.K., Vieregge P., Uitti R.J., Gasser T., Yasuhara O., McGeer P., et al. German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia: longitudinal observations. Parkinsonism Relat Disord 3 (1997) 125-139
16. Wszolek Z.K., Pfeiffer B., Fulgham J.R., Parisi J.E., Thompson B.M., Uitti R.J., et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 45 (1995) 502-505
17. Wszolek Z.K., Pfeiffer R.F., Tsuboi Y., Uitti R.J., McComb R.D., Stoessl A.J., et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62 (2004) 1619-1622
18. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., et al. LRRK2 and Lewy body disease. Ann Neurol 59 (2006) 388-393
19. Rajput A., Dickson D.W., Robinson C.A., Ross O.A., Dachsel J.C., Lincoln S.J., et al. Parkinsonism, LRRK2 G2019S, and tau neuropathology. Neurology 67 (2006) 1506-1508
20. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., et al. Biochemical and pathological characterization of LRRK2. Ann Neurol 59 (2006) 315-322
21. Gaig C., Marti M.J., Ezquerra M., Rey M.J., Cardozo A., and Tolosa E. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry 78 (2007) 626-628
22. Dachsel J.C., Ross O.A., Mata I.F., Kachergus J., Toft M., Cannon A., et al. LRRK2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathol (Berl) 113 (2007) 601-606
23. Giordana M.T., D'Agostino C., Albani G., Mauro A., Di Fonzo A., Antonini A., et al. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Mov Disord 22 (2007) 275-278